Dyne Therapeutics director granted 35,152 options

Dyne Therapeutics director Jason P. Rhodes received a grant of stock options for 35,152 shares of common stock.

Rhea-AI Filing Summary

Dyne Therapeutics director Jason P. Rhodes received a grant of stock options for 35,152 shares of common stock. The options have an exercise price of $17.04 per share and expire on June 4, 2036. The shares underlying the option are scheduled to vest in full on the earlier of June 5, 2027 or the company’s 2027 annual stockholder meeting, subject to continued service. Rhodes is obligated to transfer any economic benefit from shares issued on exercise to Atlas Venture Life Science Advisors, and he disclaims beneficial ownership except for any pecuniary interest.

Insider Trade Summary

Grant/Award: 35,152 shares

Grant/Award 1 txn

Insider Rhodes Jason P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	35,152	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 35,152 contracts (Direct)

Footnotes (2)

1. F1. This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
2. F2. The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Key Figures

Options granted: 35,152 options Exercise price: $17.04 per share Expiration date: June 4, 2036 +2 more

5 metrics

Options granted 35,152 options Grant to Jason P. Rhodes on June 5, 2026

Exercise price $17.04 per share Strike price for 35,152 options

Expiration date June 4, 2036 Option term end date

Underlying shares 35,152 shares Common stock underlying the option grant

Shares after transaction 35,152 derivative securities Total stock options held after this grant in the filing

Key Terms

Stock option, vest in full, beneficial ownership, pecuniary interest

4 terms

Stock option financial

"Stock option (right to buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vest in full financial

"shares underlying the option are scheduled to vest in full"

beneficial ownership financial

"disclaims beneficial ownership of the securities reported herein"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dyne Therapeutics (DYN) report for Jason P. Rhodes?

Dyne Therapeutics reported that director Jason P. Rhodes received a grant of stock options for 35,152 shares of common stock. These options were awarded as compensation, not as an open-market purchase or sale of existing Dyne Therapeutics shares.

What are the key terms of Jason P. Rhodes’ Dyne Therapeutics stock options?

The granted options cover 35,152 Dyne Therapeutics common shares at an exercise price of $17.04 per share. They expire on June 4, 2036, giving a long window during which Rhodes may choose to exercise them, subject to vesting conditions being satisfied.

When do Jason P. Rhodes’ Dyne Therapeutics options vest?

All 35,152 underlying Dyne Therapeutics shares are scheduled to vest in full on the earlier of June 5, 2027 or the company’s 2027 annual stockholder meeting, assuming Rhodes continues to provide service to the company through that vesting date trigger.

Does Jason P. Rhodes personally keep the economic benefit from these Dyne Therapeutics options?

Footnotes state Rhodes must transfer any economic benefit from selling shares issued on exercise to Atlas Venture Life Science Advisors. He disclaims beneficial ownership of the reported securities, except to the extent of any pecuniary interest he may ultimately have.

Are these Dyne Therapeutics option grants a buy or sell signal for investors?

The filing reflects a compensation-related option grant, not an open-market buy or sell. Such grants are common for directors and typically represent routine equity-based compensation rather than a discretionary trading decision in Dyne Therapeutics stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rhodes Jason P

(Last) (First) (Middle)

C/O DYNE THERAPEUTICS, INC.

1560 TRAPELO ROAD

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$17.04	06/05/2026		A		35,152		(1)	06/04/2036	Common Stock	35,152	$0.00	35,152	D(2)

Explanation of Responses:

1. This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

2. The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

	/s/ Ommer Chohan, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)